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Abstract
In this chapter we will discuss more about the role of homocysteine in ath-
erosclerosis and also association between serum homocysteine with extracranial 
carotid atherosclerosis. Carotid atherosclerosis comprises an increase in carotid 
intima-media (CIMT) thickening, plaque formation and carotid stenosis. 
Atherogenic property of homocysteine was discovered in 1969. Atherosclerosis is 
initiated by endothelial dysfunction. One of the causes of endothelial abnormality 
is homocysteine. The development of aggregates of homocysteinylated lipoproteins 
with microorganisms obstructs the vasa vasorum in vulnerable plaques. In one 
study, serum homocysteine in the highest quartile was independently associated 
with extracranial carotid artery stenosis ≥50%. In another study, raised serum 
homocysteine was also independently associated with severe extracranial carotid 
stenosis in both genders. In other studies, serum homocysteine was significantly 
associated with carotid artery stenosis in internal carotid arteries and external 
carotid arteries as well as the degree of stenosis. The hypertensive patients who had 
raised serum homocysteine were reported to have higher risk of developing asymp-
tomatic extracranial carotid artery stenosis.
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1. History
Premature atherosclerosis was first reported by McCully in 1969 [1]. He 
described it on two infant patients with raised homocysteine with similar arterial 
changes [1]. These two patients had large- and medium-sized arterial narrowing 
[1]. The histology was focal fibrosis of intima and media layers, focal proliferation 
of perivascular connective tissue of small arteries, as well as prominent internal 
elastic membranes in medium- and small-sized arteries [1].
Since then, numerous studies on homocysteine have been conducted. The level 
of homocysteine-cysteine mixed disulphide after a methionine load was shown to 
be slightly higher in the patients with coronary artery disease (CAD) in 1976 [2]. In 
addition, the fasting level of serum homocysteine was 31% higher in the patients 
with all vascular diseases than in controls [3]. Raised serum homocysteine was 
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found to be an independent risk factor for vascular diseases with odds ratios (OR) 
of 1.5 to 1.8 for every increase of 5 μmol/L in serum homocysteine [4]. In a meta-
analysis, raised serum homocysteine was an independent predictor of ischaemic 
stroke and CAD in the healthy population [5].
2. Introduction: molecular aspects of homocysteine
Homocysteine is a sulphur-containing amino acid which is derived from methio-
nine [6]. Methionine is activated by ATP to S-adenosylmethionine (SAM) [6]. In 
turn, S-adenosylhomocysteine (SAH) is produced from SAM by transmethylation 
process [6]. Subsequently, SAH is then hydrolysed into homocysteine [6].
Cystathionine β-synthase (CBS) has the role of catalysing the condensation of 
homocysteine together with serine into cystathionine by process of transsulfura-
tion [6]. The conversion of cystathionine into cysteine depends on pyridoxal 
5′-phosphate [6].
3. Introduction to extracranial carotid atherosclerosis
Cardiovascular diseases due to atherosclerosis include ischaemic stroke, tran-
sient ischaemic attack (TIA), CAD and peripheral vascular disease [7]. One of the 
causes of ischaemic stroke is the atherosclerosis involving the extracranial carotid 
arteries [8, 9]. Ischaemic stroke occurs secondary to ischemia caused by flow-
limiting carotid artery stenosis or by embolism due to plaque rupture [8]. 20–30% 
of ischaemic strokes in the Western countries are caused by stenosis or occlusion of 
the extracranial carotid arteries [7].
Atherosclerosis is initiated by endothelial dysfunction [10, 11]. This endothelial 
abnormality is mainly caused by free radicals, homocysteine, lipoproteins, free 
radicals and infectious agents [10, 11]. In addition, atherosclerosis develops by acti-
vation and proliferation of smooth muscle cells [10, 11]. This leads to thickening of 
the arterial wall [10, 11]. Moreover, there is infiltration of macrophages which result 
in fatty streak and plasma-derived extracellular lipid accumulation in the thickened 
intima layer [10–12].
Beginning in the mid-1980s, subclinical atherosclerosis was assessed by mea-
surement of carotid intima-media thickness with ultrasound carotid Doppler [13]. 
Later, other parameters such as carotid plaques were used to evaluate for atheroscle-
rosis [14]. These parameters of subclinical atherosclerosis are useful in assessment 
of cardiovascular diseases, such as CAD and ischaemic stroke [15–18].
The frequency of ipsilateral strokes was higher in the patients with progressive 
asymptomatic carotid stenosis than those without asymptomatic carotid stenosis 
[19]. A rate of 5.3% of developing ipsilateral strokes was observed in the patients 
with moderate asymptomatic carotid stenosis [19].
The presence of extracranial carotid artery stenosis was found to be nega-
tively associated with ideal baseline cardiovascular health in several studies 
[20, 21]. An assessment of carotid intima-media thickness (CIMT) is a good 
indicator of coronary atherosclerosis [22, 23]. In addition, CIMT is an inde-
pendent predictor of cardiovascular mortality [22, 23]. Moreover, reduced 
frequency of subclinical atherosclerosis is associated with ideal cardiovascular 
health profile [24]. Several large population studies showed that there was an 
association between increased CIMT with future cardiovascular events [25]. 
In the Multi-Ethnic Study of Atherosclerosis (MESA), Zhang et al. reported 
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that measurement of CIMT with magnetic resonance imaging (MRI) was more 
consistently associated with incident cardiovascular diseases (especially stroke) 
than ultrasound carotid [26].
The presence of carotid plaque helps in the identification of the patients with 
coronary atherosclerosis [14]. The baseline plaque area is believed to be more than 
3.4 times more powerful than the Framingham risk Equation [27]. The patients with 
plaque scores in the highest quartile had 3.4 times higher risk of stroke, myocardial 
infarction and overall mortality in the last 5 years than those in the lowest quartile 
[27]. Measurement of plaque area is a sensitive parameter to assess atheroscle-
rosis [28]. In a recent study by Kaspar et al., ultrasound-based carotid plaque 
analysis techniques are more promising for future research studies on generalised 
 atherosclerosis [25].
4. Pathophysiology
Raised serum homocysteine results in endothelial dysfunction as manifested by 
changes in endothelial cell structure and function [29, 30]. The hypothesised mech-
anisms were pro-inflammatory effects (expression of tumour necrosis factor-α and 
inducible nitric oxide (NO) synthase), oxidative stress and impaired endothelium-
mediated platelet inhibition [31–33]. In addition, raised serum homocysteine leads 
to a decrease in nitric oxide bioavailability and inflammation [30].
The autoxidation of homocysteine produces oxidative stress [32]. Raised serum 
homocysteine-related pathologies such as atherosclerosis and thrombosis are 
believed to be due to oxidative stress [34–37]. Hydroxyl free radicals due to raised 
serum homocysteine level remove electrons from other molecules including DNA, 
proteins, lipids and carbohydrates in all the cellular components [34–37]. In addi-
tion, the hydroxyl free radicals stimulate lipid oxidation and accumulate intracel-
lular cholesterol [33]. Raised serum homocysteine level increases the adhesion 
between the endothelial cells and neutrophils, resulting in release of extracellular 
hydrogen peroxide which damages the endothelial cell [38].
Homocysteine is important in vascular function and atherosclerosis [39]. Ozone 
activates thioretinaco to produce thioretinaco ozonide which is the active site for 
oxidative phosphorylation [40]. In addition, ozone has been discovered to be pres-
ent in human atherosclerotic plaques, thus emphasising the important role of ozone 
and cholesterol ozonolysis in atherosclerosis [41]. Aggregates of microorganisms, 
homocysteinylated and oxidised low-density lipoproteins (LDL) and lipoprotein 
autoantibodies in regions of high pressure lead to obstruction of the vasa vasorum 
[39, 42, 43]. This in turn results in ischaemia and rupture into arterial intima to 
form the vulnerable plaque [39, 42, 43].
Endothelial cell hyperplasia and fibrin deposition in the walls of arterioles may 
worsen the degree of obstruction of the vasa vasorum by lipoprotein aggregates [1]. 
Homocysteine activates the proliferation of endothelial cells by inhibiting the nitric 
oxide production by platelets and endothelial cells [37, 44]. Subsequently, produc-
tion of glutathione peroxidase is suppressed, and this results in a rise of amount of 
arachidonic acid from platelets to produce more reactive oxygen species [37].
Homocysteine initiates the coagulation process by tissue factor pathway [45]. 
Homocysteine activates platelet production of the thromboxane A2, a vasoconstric-
tor and pro-aggregant [46]. Moreover, homocysteine causes thrombosis by inhibit-
ing tissue plasminogen activator binding domain of annexin II [47]. Homocysteine 
suppresses the activation of protein C and thrombomodulin surface expression [48] 
as well as increases the adhesion of platelets [49].
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5. Factors affecting serum homocysteine level
Genetic polymorphisms of the metabolic genes, such as methylenetetrahydrofo-
late reductase (MTHFR), cystathionine-beta-synthase (CBS), DNA methyltransfer-
ase (DNMT) and nicotinamide N-methyl-transferase (NNMT), results in increased 
level of homocysteine [50, 51]. This leads to an increased risk of ischaemic stroke 
[50, 51]. CBS deficiency is the most common cause of homocysteinemia due to 
genetic cause [52]. In the mutation in the gene coding for the enzyme MTHFR, 
cytosine is replaced by thymidine (C → T) at the base position 677 of the gene [53]. 
The carriers have nearly 70% reduction in the enzymatic activity [53]. Therefore, 
the carriers have 20% increase of serum homocysteine concentrations [54]. 
Deficiencies in CBS and MTHFR result in very high serum homocysteine levels [55].
Nutritional and metabolic abnormalities can also result in elevated serum 
homocysteine [42]. Metabolism of homocysteine involves remethylation to methio-
nine requiring folate and vitamin B12-derived methylcobalamin [56]. Furthermore, 
in the process of transsulfuration to cystathionine, vitamin B6-derived pyridoxal 
5′-phosphate is needed [56]. Nutritional deficiencies in the vitamin B cofactors 
inhibit the metabolism of homocysteine metabolism, and this causes an elevated 
level of serum homocysteine [56].
Serum homocysteine level was significantly higher in the patients with people 
with impaired renal function [57]. In various studies, gender was significantly 
correlated with serum homocysteine [53, 58]. However, in some other studies, there 
was no variation in gender [59].
Parkinsonism and antiepileptic medications have been reported to lead to raised 
serum homocysteine [60–63]. Paradoxically, lipid-lowering medications have also 
been reported to cause raised serum homocysteine [60, 63]. The patients with 
diabetes mellitus (DM) have higher homocysteine than nondiabetics irrespective of 
gender and ethnic group [64, 65]. Malignancy also leads to higher concentration of 
homocysteine [66].
6. Factors affecting extracranial carotid atherosclerosis
Atherosclerosis involves inflammation, intimal injury, proliferation of smooth 
muscle cells and lipid metabolism [67, 68]. In the Framingham study, fasting 
cholesterol level, systolic blood pressure (SBP), age and status of smoking were 
significantly associated with the degree of extracranial carotid stenosis in both gen-
ders [69]. In the study by Zhu et al., age was correlated positively with CIMT [70]. 
Hyperlipidaemia, hypertension, DM and smoking were thought to be associated 
with endothelial dysfunction [71]. In another study, there was positive correlation 
between incidence of smoking and hypertension with the severity of presentation 
of extracranial carotid artery stenosis [72].
In a recent study, CIMT and carotid plaques were associated with hypertension, 
DM and hyperlipidaemia [73]. Male gender has an increased risk of ischaemic stroke 
in comparison to female gender for all degrees of carotid stenosis [74, 75]. After the age 
of 85, female gender had a higher risk of stroke [76]. Carotid plaques present in female 
gender contain reduced level of pro-inflammatory cytokine and more smooth muscle 
cell content [77]. Female gonadal hormones provide protective effect by causing favour-
able lipid profile change and by increasing neuronal viability and cerebral blood flow 
[78, 79]. Oestrogen protects premenopausal women against atherosclerosis [78, 79].
Various ethnic groups have different associations with vascular risk factors [80]. 
Therefore, these ethnic groups have varying prothrombotic factors and degrees of 
plaque rupture [80]. Particularly, South Asians have increased serum homocysteine 
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levels in comparison to Chinese and European patients [80]. Kim et al. reported that 
serum homocysteine is a predictor of asymptomatic carotid stenosis in the patients 
undergoing coronary artery bypass surgery (CABG) [81].
7. Homocysteine and extracranial carotid artery stenosis
Kim et al. reported that serum homocysteine in the highest quartile was inde-
pendently associated with extracranial carotid artery stenosis ≥50% [81]. In another 
study, raised serum homocysteine was also independently associated with severe 
extracranial carotid stenosis in both genders [82]. In other studies, serum homo-
cysteine was significantly associated with carotid artery stenosis in internal carotid 
arteries and external carotid arteries as well as the degree of stenosis [83, 84]. The 
hypertensive patients who had raised serum homocysteine were reported to have 
higher risk of developing asymptomatic extracranial carotid artery stenosis [85]. 
However, other studies showed conflicting results [86–87].
In a community-based study, serum homocysteine >19.3 μmol/L was associated 
with asymptomatic carotid artery stenosis in the non-smoker participants aged 
≥40 without transient ischemic attack and coronary artery disease [21]. In addi-
tion, raised serum homocysteine was associated with asymptomatic carotid artery 
stenosis in the diabetic patients [21]. Wang et al. reported that serum homocysteine 
level of ≥15 μmol/L was a predictor of extracranial carotid stenosis [20] and serum 
homocysteine level > 14.4 μmol/L was associated with increased extracranial carotid 
stenosis ≥25% in the elderly people [88], whereas Samson et al. reported that serum 
homocysteine >10 μmol/L was associated with carotid artery stenosis [89].
Every 1 μmol/L increase of total homocysteine level was associated with 1.12 
times the risk for developing internal carotid artery (ICA) occlusion after adjust-
ment for stroke subtypes and risk factors [90]. In the study conducted by Wang 
et al., every 1 μmol/L increase of total homocysteine level was associated with 1.096 
times the risk of developing extracranial carotid stenosis [20]. In addition, Mueller 
et al. identified serum homocysteine as independent predictor of ICA stenosis 
≥50%, with OR 1.32 (95% CI: 1.02–1.72) for every rise of 5 μmol/L [91].
In a previous study, elevated serum homocysteine level is associated with a 
higher prevalence of 40–100% extracranial carotid arterial disease (ECAD) in 
older patients [92]. In this study, high serum homocysteine levels were seen in 45% 
of the older male patients with 40–100% ECAD, whereas only in 20% of the older 
men with 0–39% ECAD [92]. In addition, elevated serum homocysteine levels were 
found in 40% of the older female patients with 40–100% ECAD versus 18% of the 
older women with 0–39% ECAD [92].
Elevated serum homocysteine levels were also associated with a higher preva-
lence of coronary artery disease (CAD) and peripheral artery disease in older 
patients [93, 94]. In another study, the significant independent predictors of new 
cerebral infarction in older patients were serum homocysteine, age, smoking, 
diabetes mellitus, hypertension and previous cerebral infarcts [95].
Moreover, in a previous study, the significant independent predictors of new-
onset CAD in older patients were serum homocysteine, age, smoking, diabetes 
mellitus, hypertension and hyperlipidaemia [96].
8. Homocysteine and carotid plaque
Increased serum homocysteine level was associated with 1.344 higher risk of 
developing carotid plaque [97]. Plaque area was reported to be increased in the 
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patients with raised serum homocysteine level [98, 99]. Furthermore, the pres-
ence of complicated atheromatous plaque was significantly associated with serum 
homocysteine level [98].
The patients with serum homocysteine level > 15 μmol/L had increased risk of 
presence of carotid plaque and plaque in bilateral common carotid artery (CCA) 
[100]. An increase in serum homocysteine was independently associated with 
plaque morphology and larger plaque area [101].
The patients with serum homocysteine level of ≥8.6 μmol/L had higher risk 
of developing echolucent plaques [101]. In another study, the patients with 
raised serum homocysteine level had 1.28 times risk of developing advanced 
carotid plaques after adjustment for age and gender [102]. Advanced carotid 
plaques were defined as ulcerated plaque and plaques with incomplete fibrous 
cap [102]. These advanced carotid plaques resulted in a higher ischaemic stroke 
risk [102]. In the study by Zhang et al., raised serum homocysteine acted syner-
gistically with hypertension; therefore there was a greater risk of having plaque 
in bilateral CCA [100]. Alvarez et al. reported that in the patients with carotid 
stenosis of more than 70% and were receiving surgical management, high 
homocysteine level was present in the patients with extracranial cerebrovascular 
diseases [103].
9. Homocysteine and carotid intima-media thickness
An increase in homocysteine level was significantly associated with an increase 
in CIMT carotid intima-media thickness [104]. In a study on the patients with 
primary hypertension, serum homocysteine level was independently associated 
with CIMT [105]. A significant positive correlation between homocysteine and 
intima-media thickness was reported [106]. In another study conducted among the 
patients with Parkinson’s disease receiving treatment, there was positive correlation 
with statistical significance between CIMT and serum homocysteine level [107]. 
The patients with raised serum homocysteine as well as hypertension had higher 
risk of increased CIMT [100].
10. Association of serum homocysteine with atherosclerosis
According to Wu et al., there was correlation between serum homocysteine level 
with carotid intima-media thickness and total number of plaques and unstable 
plaques [84]. He also reported that serum homocysteine level was correlated with 
stenosis of ICAs and external carotid arteries (ECA) [84]. In a study on middle-
aged asymptomatic women, serum homocysteine was significantly associated with 
atherosclerosis change after adjustment for age, LDL, diastolic blood pressure and 
body mass index [108].
In conclusion, raised serum homocysteine should be diagnosed early as this 
can lead to increased CIMT, carotid plaque and extracranial carotid stenosis. 
Raised serum homocysteine level can be managed with folic acid and vitamin 
supplementation.
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